Replies to post #389546 on Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Perhaps this will add a little clarity.

All Brilacidin treatment regimens were well tolerated. There were six severe adverse events (SAE) reported across the study, none of which were considered related to Brilacidin by the principal investigator.

This is an historic event and a proud day for Cellceutix shareholders as we have proven the efficacy of one dose of our novel drug Brilacidin to be comparable to seven days of therapy with the blockbuster antibiotic daptomycin to treat ABSSSI with zero drug-related SAEs ,

http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin?rq=brilacidin%2Fdaptomycin

Message in reply to:

No. It appeared to be equally effective according to the limited data released by IPIX, but had more than twice the number of adverse events than the comparator. [Emphasis added]

[TradingPro]

We’ve been through the AE discussion before. Your claims are very misleading. As for efficacy, it was clearly superior.